See more : Shandong Gold Mining Co., Ltd. (1787.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Polyrizon Ltd. (PLRZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polyrizon Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Singularity Future Technology Ltd. (SGLY) Income Statement Analysis – Financial Results
- Evonik Industries AG (EVK.SW) Income Statement Analysis – Financial Results
- PT Andalan Sakti Primaindo Tbk (ASPI.JK) Income Statement Analysis – Financial Results
- Siel Financial Services Limited (SIELFNS.BO) Income Statement Analysis – Financial Results
- J.K. Cement Limited (JKCEMENT.BO) Income Statement Analysis – Financial Results
Polyrizon Ltd. (PLRZ)
About Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
Polyrizon Announces Closing of $4.2 Million Initial Public Offering
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
Source: https://incomestatements.info
Category: Stock Reports